Bristol-Myers Squibb Company
Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit

Abstract:

In antibody-drug conjugates having tubulysin analog as the warhead, according to formula (III) ##STR00001## the acetate group in the Tuv subunit (dotted box) demonstrates improved stability against hydrolytic cleavage.